Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.
Gretchen E WhiteIngrid ShuDavid RometoJon ArnoldMary KorytkowskiJing LuoPublished in: Obesity (Silver Spring, Md.) (2023)
In this real-world study of more than 2400 patients with overweight or obesity and type 2 diabetes, starting a GLP-1 agonist at standard glycemic control doses was associated with modest weight loss through 72 weeks.
Keyphrases
- weight loss
- glycemic control
- bariatric surgery
- type diabetes
- roux en y gastric bypass
- blood glucose
- gastric bypass
- weight gain
- randomized controlled trial
- systematic review
- obese patients
- insulin resistance
- cardiovascular disease
- body mass index
- gestational age
- physical activity
- adipose tissue
- skeletal muscle
- high fat diet induced